CL2020002166A1 - Formas de dosificación y métodos para el bupropión enriquecido enantioméricamente o puro. - Google Patents
Formas de dosificación y métodos para el bupropión enriquecido enantioméricamente o puro.Info
- Publication number
- CL2020002166A1 CL2020002166A1 CL2020002166A CL2020002166A CL2020002166A1 CL 2020002166 A1 CL2020002166 A1 CL 2020002166A1 CL 2020002166 A CL2020002166 A CL 2020002166A CL 2020002166 A CL2020002166 A CL 2020002166A CL 2020002166 A1 CL2020002166 A1 CL 2020002166A1
- Authority
- CL
- Chile
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- pure bupropion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002166A1 true CL2020002166A1 (es) | 2020-10-23 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002166A CL2020002166A1 (es) | 2018-02-23 | 2020-08-21 | Formas de dosificación y métodos para el bupropión enriquecido enantioméricamente o puro. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (https=) |
| JP (3) | JP2021513998A (https=) |
| KR (3) | KR20230075531A (https=) |
| CN (2) | CN112087999A (https=) |
| AU (3) | AU2019223187B2 (https=) |
| BR (1) | BR112020017179A2 (https=) |
| CA (1) | CA3092076A1 (https=) |
| CL (1) | CL2020002166A1 (https=) |
| CR (1) | CR20200415A (https=) |
| EC (1) | ECSP20060179A (https=) |
| IL (2) | IL276871B2 (https=) |
| MA (1) | MA51914A (https=) |
| MX (2) | MX2020008704A (https=) |
| MY (1) | MY202993A (https=) |
| NI (1) | NI202000056A (https=) |
| NZ (1) | NZ767378A (https=) |
| PE (1) | PE20211752A1 (https=) |
| SG (1) | SG11202008056SA (https=) |
| WO (1) | WO2019165379A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3092076A1 (en) * | 2018-02-23 | 2019-08-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| KR20220066930A (ko) * | 2019-09-20 | 2022-05-24 | 액섬 테라퓨틱스, 인크. | 에난티오머적으로 풍부한 또는 순수한 부프로피온을 위한 제형 및 방법 |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| WO2025259728A1 (en) * | 2024-06-13 | 2025-12-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002501890A (ja) * | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（＋）−ビュープロピオンの薬学的使用 |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| ME00391B (me) * | 2003-08-08 | 2011-10-10 | Biovail Laboratories Int Srl | Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| CA3092076A1 (en) * | 2018-02-23 | 2019-08-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2019
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko active Pending
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt not_active Application Discontinuation
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023009281A (es) | 2023-08-17 |
| CR20200415A (es) | 2021-02-03 |
| NZ767378A (en) | 2024-03-22 |
| JP2021513998A (ja) | 2021-06-03 |
| WO2019165379A1 (en) | 2019-08-29 |
| KR20230075531A (ko) | 2023-05-31 |
| KR20240091043A (ko) | 2024-06-21 |
| ECSP20060179A (es) | 2020-12-31 |
| MA51914A (fr) | 2020-12-30 |
| NI202000056A (es) | 2021-01-11 |
| IL276871A (en) | 2020-10-29 |
| AU2022204521A1 (en) | 2022-07-21 |
| EP3755312A1 (en) | 2020-12-30 |
| EP3755312A4 (en) | 2022-03-16 |
| CA3092076A1 (en) | 2019-08-29 |
| AU2019223187B2 (en) | 2022-07-28 |
| AU2019223187A1 (en) | 2020-09-17 |
| BR112020017179A2 (pt) | 2020-12-22 |
| JP2024075655A (ja) | 2024-06-04 |
| MX2020008704A (es) | 2020-12-07 |
| IL276871B2 (en) | 2024-11-01 |
| AU2022204521B2 (en) | 2024-09-05 |
| MY202993A (en) | 2024-05-31 |
| IL313368A (en) | 2024-08-01 |
| JP2022153638A (ja) | 2022-10-12 |
| CN112087999A (zh) | 2020-12-15 |
| PE20211752A1 (es) | 2021-09-06 |
| SG11202008056SA (en) | 2020-09-29 |
| IL276871B1 (en) | 2024-07-01 |
| CN120827545A (zh) | 2025-10-24 |
| KR20210003091A (ko) | 2021-01-11 |
| AU2024205858A1 (en) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002166A1 (es) | Formas de dosificación y métodos para el bupropión enriquecido enantioméricamente o puro. | |
| MX2016010235A (es) | Composicion farmaceutica que comprende eritrocitos que encapsulan una enzima dependiente de fosfato de piridoxal (plp) y su cofactor. | |
| UY36703A (es) | Composiciones y métodos para la administración de un polinucleótido en una planta | |
| UY32388A (es) | Composicion farmaceutica sólida que comprende amlodipina y losartan con estabilidad mejorada | |
| ECSP18015616A (es) | Tableta | |
| MX394496B (es) | Administracion de metabolitos de berberina | |
| USD787607S1 (en) | Word game components set | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| WO2012097116A3 (en) | Isotopologues of isoindole derivatives | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| AR055682A1 (es) | Forma de dosificacion osmotica con aspectos de liberacion controlada y de liberacion rapida | |
| ECSP22030119A (es) | Formas de dosificación y métodos para bupropión enantioméricamente enriquecido o puro | |
| BR112018074434A2 (pt) | composições farmacêuticas compreendendo safinamida | |
| MX381450B (es) | Un medicamento combinado que comprende fenilefrina y paracetamol | |
| MY203254A (en) | Pharmaceutical preparation | |
| HK40068404A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| HK40041795A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| Kistanova | Genre Of Ode in 17–18th Centuries English Poets ‘Theoretical Reflection (A. Cowley, W. Congreve, E. Young) | |
| CO2019008347A2 (es) | Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla | |
| AR103767A1 (es) | Forma de dosificación de liberación controlada con farmacocinética mejorada | |
| UA93429U (uk) | Спосіб підвищення ефективності профілактики судинних ускладнень у хворих на остеоартроз | |
| MX2015016506A (es) | Una mezcla enriquecida con la estereoquimica r,r de 3',4'-di-o-acetil-cis-quelactona para el tratamiento de la diabetes mellitus. |